The global race to develop so-called “double G” and “triple G” agonists is heating up to boost the efficacy of…
HOME > BUSINESS
BUSINESS
- Otsuka to Launch Deltyba on September 26; Launch Delayed in Anticipation of Revised TB Treatment Guidelines
September 10, 2014
- Medical & Biological Lab Seeking Partner for Dengue Fever Drug Development
September 9, 2014
- Announcement: Sales Excellence Japan 2014 to Be Held on October 14, 15
September 9, 2014
- Ethical Drug Sales Down 3.0% in July: Crecon Report
September 9, 2014
- Ono, Bristol-Myers Sue Merck over Anti-PD-1 Antibody Patent
September 9, 2014
- Chugai Launches ALK Inhibitor Alecensa
September 9, 2014
- Pfizer Japan, Astellas to Terminate Copromotion Deal for Caduet in March Next Year
September 9, 2014
- MSD Sales Structure Now Tailored to Local Healthcare Needs: Pres.
September 8, 2014
- All Eyes Glued to Japan Realignment after Mylan’s Buyout of Abbott’s Established Product Biz
September 8, 2014
- Meiji Seika Pharma, Takeda to Copromote Insomnia Treatment Rozerem from October
September 8, 2014
- Bayer Yakuhin Files Eylea for Macular Edema Secondary to Branch Retinal Vein Occlusion
September 8, 2014
- Takeda Files Leuplin 6-Month Depot Formulation in Japan
September 8, 2014
- MSD’s Januvia Logs 1st Sales Decline in Japan on Re-Pricing
September 5, 2014
- Januvia Retains Its No. 1 Spot in the GP Market in July: Anterio’s “Mind Share” Ranking
September 5, 2014
- Takeda Transfers All Shares of Its Subsidiary Nippon-Rinshosha to Medical Tribune
September 5, 2014
- Sanofi Launches Prostate Cancer Agent Jevtana
September 5, 2014
- Kaketsuken Completes New Manufacturing Plant for Increasing Production Capacity of Hepatitis B Vaccine
September 5, 2014
- US Court Backs Jury Verdict in Actos Suit, Orders Takeda to Pay US$6 Billion in Punitive Damages
September 5, 2014
- TMRC to Collaborate with Children’s Hospital Los Angeles to Develop Treatment for Chemotherapy-Induced Neutropenia
September 4, 2014
- Bristol-Myers’ Dual Oral Hepatitis C Regimen Debuts in Japan
September 4, 2014
ページ
1. Build a Strong Employer BrandFirst up, let’s talk about your employer brand. Think of it as your company’s personality and reputation. In Japan’s competitive pharmaceutical and medical device industry, it’s crucial to stand out. You need to showcase your…
A Japanese health ministry panel on December 26 wrapped up its discussions on the next amendment of the Pharmaceuticals and…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s key reimbursement policy panel on December 25 approved an outline of the FY2025 drug price revision, finalizing plans to…
For the first time in many years, Japan appeared to have pivoted to a pro-innovation path with the FY2024 drug pricing reform. All eyes were apparently on this course change as seen in this year’s most-read story list, though the…
A Japanese health ministry panel discussing the generic industry structure on May 22 put together a report in which it…
A Japanese health ministry study group focused on pharmaceutical regulations on March 21 agreed on a policy to encourage the…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…
The Japanese health ministry’s expert panel tasked to discuss comprehensive policies for the rapid and stable supply of pharmaceuticals generally…